
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Please let us know what you are thinking by taking our latest poll and see what your colleagues have to say. Results from our past surveys are here too.






